Metraipolis › archive › dc_e7a80ae84bc2
Results of a non-randomized, open-label phase I study evaluating the novel immunomodulatory peptide TCP-25 for treatment of dystrophic epidermolysis bullosa — Europe PMC PMID:41327356
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41327356
- DOI
- 10.1186/s13023-[numero omesso]-7
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T01:03:46.265Z
- SHA-256 of the archived text
16656a13ea75df882e7ea4047d70c90184d55b387dde72fa977123c2b41d7324- Stable URL of this page
https://metraipolis.com/documento/dc_e7a80ae84bc2
How to cite
Results of a non-randomized, open-label phase I study evaluating the novel immunomodulatory peptide TCP-25 for treatment of dystrophic epidermolysis bullosa — Europe PMC PMID:41327356 — Europe PMC (en), https://europepmc.org/article/MED/41327356 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e7a80ae84bc2 (Metraipolis archive dc_e7a80ae84bc2, sha256 16656a13ea75df882e7ea4047d70c90184d55b387dde72fa977123c2b41d7324)
BibTeX
@misc{dce7a80ae84bc2,
title = {Results of a non-randomized, open-label phase I study evaluating the novel immunomodulatory peptide TCP-25 for treatment of dystrophic epidermolysis bullosa — Europe PMC PMID:41327356},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41327356},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e7a80ae84bc2; sha256 16656a13ea75df882e7ea4047d70c90184d55b387dde72fa977123c2b41d7324},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41327356. Agents can read the archived copy with the MCP tool read_document.